AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

Recruitingn/aAges 18 Years - anyAllFondazione IRCCS Istituto Nazionale dei Tumori, Mโ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

I3LUNG is an international project aiming to develop a medical device to predict immunotherapy efficacy for NSCLC patients using the integration of multisource data (real word and multi-omics data). This objective will be reached through a retrospective - setting up a transnational platform of available data from 2000 patients - and a prospective - multi-omics prospective data collection in 200 NSCLS patients - study phase. The retrospective cohort will be used to perform a preliminary knowledge extraction phase and to build a retrospective predictive model for IO (R-Model), that will be used in the prospective study phase to create a first version of the PDSS tool, an AI-based tool to provide an easy and ready-to-use access to predictive models, increasing care appropriateness, reducing the negative impacts of prolonged and toxic treatments on wellbeing and healthcare costs. The prosp

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Age \>/= 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status \</= 2. * Histologically confirmed diagnosis of stage IIIB/C-IV Non-Small-Cell Lung Cancer * Received any line immunotherapy (maintenance therapy with Durvalumab is allowed) for retrospective cohort; clinical indication for frontline treatment with immunotherapy as first line treatment for prospective cohort. * Patients with CNS metastasis are allowed * Patients with driver genomic alterations are allowed (only for retrospective cohort) * Evidence of a personally signed and dated ICF indicating that the patient has been informed of and understands all pertinent aspects of the study before enrolment (only for prospective cohort) * Availability of at least one FFPE block for -omics data generation (only for prospective cohort) Exclusion Criteria: * Patients without minimal treatment information data to be included in the retrospective cohort * Prior treatment for advanced disease (only for prospective cohort) * Unavailability or inability to comply with the requested study procedures, including compilation of QoL questionnaires
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

4 sites
University of Chicago
Chicago, United States
Metropolitan Hospital
Athens, Greece
Shaare Zedek Medical Center
Jerusalem, Israel
Vall D'Hebron Institute of Oncology
Barcelona, Spain
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy